MaxCyte (NASDAQ:MXCT – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Analyst Ratings
This is a summary of current recommendations and price targets for MaxCyte and CryoPort, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 2 | 1 | 0 | 2.00 |
| CryoPort | 0 | 2 | 7 | 0 | 2.78 |
MaxCyte currently has a consensus target price of $5.00, indicating a potential upside of 367.29%. CryoPort has a consensus target price of $16.38, indicating a potential upside of 5.71%. Given MaxCyte’s higher possible upside, analysts clearly believe MaxCyte is more favorable than CryoPort.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -121.16% | -20.03% | -17.14% |
| CryoPort | 41.57% | -7.92% | -4.79% |
Insider and Institutional Ownership
68.8% of MaxCyte shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares MaxCyte and CryoPort”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | 3.47 | -$44.63 million | ($0.37) | -2.89 |
| CryoPort | $176.18 million | 4.43 | $78.30 million | $1.35 | 11.47 |
CryoPort has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
MaxCyte has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.
Summary
CryoPort beats MaxCyte on 12 of the 13 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
